Press Releases

Press Releases

All Releases
May 11, 2015
- Conference Call and Webcast Today , May 11, 2015 at 5:00 p.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq: OPHT) today announced the completion of patient recruitment of its first Phase 3 trial of Fovista ® in combination with Lucentis ® (ranibizumab).
May 06, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Bank of America Merrill Lynch 2015 Health
May 05, 2015
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its first quarter 2015 financial results after close of market on Monday, May 11, 2015 . Following the announcement, Ophthotech's management will host a live conference call and webcast at 5:00
May 04, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Deutsche Bank 40 th Annual Health Care
Mar 10, 2015
- Milestone Triggered by Reaching Second Enrollment Goal in the Fovista ® Phase 3 Program - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a second $50 million enrollment milestone from Novartis Pharma AG as part of the ex-US licensing
Mar 03, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare
Feb 23, 2015
- Conference Call and Webcast Today, February 23 , at 5:00 p.m. ET - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2014 and provided an update on the Company's business and product
Feb 18, 2015
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2014 financial results will be released on Monday, February 23, 2015 . Following the announcement, Ophthotech's management will host a live conference call and
Feb 05, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Leerink Global Healthcare Conference in New
Jan 05, 2015
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 33rd Annual J.P.
Dec 15, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ: OPHT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014 .
Dec 02, 2014
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chairman of the Board and Chief Executive Officer, will present an overview of the Company at the Oppenheimer 25 th Annual Healthcare
Nov 13, 2014
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Stifel 2014 Healthcare Conference in New
Nov 11, 2014
- Conference Call and Webcast, Today, November 11 , at 8:00 a.m. ET - - Ophthotech Achieves Enrollment Milestone Triggering Third and Final Tranche in Royalty Financing with Novo A/S - - Ophthotech Signs Research and Exclusive Option Agreement to License a VEGF Tyrosine Kinase Inhibitor for the
Nov 04, 2014
- Webcast Available Through Ophthotech Website - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2014 Credit Suisse Annual Healthcare
Nov 03, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014 , on Tuesday, November 11, 2014 . Following the announcement, Ophthotech's management will host a live conference call and
Oct 03, 2014
- Ophthotech Broadens and Strengthens its Senior Leadership Team - - Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) announced that Todd N. Smith has joined the Company today as Senior Vice President and Chief
Sep 23, 2014
- Bruce A. Peacock's Planned Retirement to be Effective at the End of September - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September
Sep 16, 2014
- Presentation Will Occur at the 2014 American Academy of Ophthalmology Annual Meeting - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that a subgroup analysis assessing the development and progression of sub-retinal fibrosis in the Company's Phase 2b trial
Sep 08, 2014
- Initial Milestone Payment Triggered by Reaching First Enrollment Goal in the Fovista ® Phase 3 Program - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the